Palantir a high-risk investment with ’a one-of-a-kind growth and margin model’
Daniel Rabinowitz, the Secretary and Chief Legal Officer of Natera, Inc. (NASDAQ:NTRA), recently sold shares of the company’s stock, according to a filing with the Securities and Exchange Commission. On March 31, Rabinowitz sold a total of 1,404 shares at prices ranging from $138.3874 to $138.4101, resulting in a transaction value of $194,326. The sale occurred near the current trading price of $140.66, with the stock showing remarkable strength, having gained over 53% in the past year. According to InvestingPro analysis, Natera maintains a strong financial health score and operates with a moderate debt level.
Earlier, on March 28, Rabinowitz acquired 2,500 shares through the vesting of Restricted Stock Units (RSUs), which were granted as part of a stock unit agreement. This acquisition was completed at no cost, as each RSU represents a contingent right to receive one share of the company’s common stock. The sale of shares was conducted to satisfy tax withholding obligations related to the vesting of these RSUs. Following these transactions, Rabinowitz holds 225,281 shares of Natera, representing a stake in this $19.08 billion market cap company. For deeper insights into Natera’s valuation and growth prospects, including 11 additional key ProTips, check out the comprehensive research report available on InvestingPro.
In other recent news, Natera Inc . reported its fourth-quarter 2024 earnings, exceeding Wall Street expectations with a revenue of $476 million, a 53% year-over-year increase, and a narrower-than-expected loss per share of -$0.41. The company’s gross margins improved significantly to 63%, and it generated $46 million in cash flow during the quarter. Analysts at TD Cowen and Canaccord Genuity have maintained their Buy ratings on Natera, with both firms setting a price target of $195, citing strong sales projections and robust growth levers, including the anticipated rise in Signatera’s price and volume. Canaccord Genuity highlighted Natera’s consistent financial performance, noting positive operating cash flows for four consecutive quarters and a promising outlook for 2025 with expected revenue growth in the mid-20% range.
Additionally, Natera has launched the HEROES clinical trial to explore treatment de-escalation in metastatic HER2+ breast cancer patients, aiming to assess the feasibility of ctDNA-guided treatment. This trial, sponsored by Unicancer and funded by the French Ministry of Health, could significantly impact oncologists’ approach to treating this type of cancer. Natera’s advancements in molecular diagnostics and strategic spending on operational expenses have been recognized as key factors contributing to its positive financial outlook. The company’s strategic focus includes expanding reimbursement strategies and payer coverage to enhance revenue per test.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.